Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 9/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30570407 | 1.00 | CASP3 (0.38) | CASP3SENP7FFAR2PTGESPTGS2 | |
| SCHEMBL26227697 | 0.90 | PTGES (0.39) | CASP3SENP7PTGESPTGS2MAPT | |
| SCHEMBL24470360 | 0.89 | MAPT (0.39) | PTGESPTGS2MAPTNPSR1NPC1 | |
| SCHEMBL30570406 | 0.89 | MAPT (0.39) | PTGESPTGS2MAPTNPSR1NPC1 | |
| SCHEMBL30570410 | 0.89 | PTGES (0.38) | PTGESPTGS2MAPTNPSR1NPC1 | |
| SCHEMBL26227707 | 0.89 | PTGES (0.38) | PTGESPTGS2MAPTNPSR1NPC1 | |
| SCHEMBL26227682 | 0.89 | HPGD (0.44) | PTGESPTGS2MAPTNPSR1NPC1 | |
| SCHEMBL29568727 | 0.88 | PTGES (0.38) | CASP3SENP7PTGESPTGS2MAPT | |
| SCHEMBL26227885 | 0.88 | PTGES (0.38) | CASP3SENP7PTGESPTGS2MAPT | |
| SCHEMBL30570396 | 0.87 | TRPV1 (0.38) | CASP3SENP7FFAR2PTGESPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286969-A1 | AROMATIC SPIRO RING AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286969-A1 | AROMATIC SPIRO RING AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286969-A1 | AROMATIC SPIRO RING AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, NR1H4, SLC10A1 | CASP3 2466/4885SENP7 4311/4885FFAR2 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.